ABCL: AbCellera Biologics Company Value to Net Income

abcellera.com - graphic logo of issuer ABCL

Retaining rare specialists at the intersection of IT and biology stabilizes the development of AbCellera Biologics (ABCL). The business valuation based on P/E demonstrates price dynamics where the -25.10 metric determines this level. Growth is driven by cloud-based AI antibody discovery and partner royalties. Meanwhile, high-end laboratories and grants ensure the loyalty of leading scientists, creating a reliable foundation for scaling.

AbCellera Corp (ABCL) Price to Earnings Ratio: for the period 07/04/2022 - 11/14/2026

Analytical breakdowns for AbCellera Biologics (ABCL)

- price and consensus price forecast:
Stock Price AbCellera Corp|ABCL - Consensus Target
- market capitalization information:
Market Value AbCellera Biologics Inc.|ABCL - Enterprise Value
- balance sheet net asset value indicators:
Net Assets per Share AbCellera|ABCL - Company Book Value|Market Cap to Net Assets Ratio abcellera.com|ABCL - Aggregate Company Assets
- debt and solvency information:
Total Debt to Equity Ratio AbCellera Biologics|ABCL - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital abcellera.com|ABCL - Company Debts|Debt to Book Value Ratio AbCellera Biologics Inc.|ABCL - Company Long-Term Debts|Short-Term Debt AbCellera|Quick Ratio abcellera.com
- earnings and market multiples details:
ABCL - Net Profit|Expected Profit AbCellera Biologics|ABCL - P/E Multiple|Projected Price to Earnings AbCellera Biologics Inc|ABCL - PEG Multiple|Company Value to EBITDA AbCellera Biologics Inc.|ABCL - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months AbCellera|ABCL - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last twelve months abcellera.com|ABCL - Earnings growth in current year|Expected net earnings per share growth next year AbCellera Biologics
- sales volume and revenue indicators:
ABCL - Company Revenue|Company Future Revenue AbCellera Biologics|ABCL - P/S Multiple|Forward P/S Multiple AbCellera Biologics Inc.
Comprehensive company analysis:AbCellera Biologics Inc. ABCL
Signature product of AbCellera Biologics

For AbCellera Biologics (ABCL), the price-to-earnings ratio reflects market expectations regarding the monetization of its AI platform and patent portfolio amid stringent FDA oversight. By analyzing changes in the company's P/E ratio, investors can assess the premium paid for the asset, determining the extent to which current capitalization is justified by actual business returns and its technological advantage over competitors.

Key competitors

P/E Multiple argenx.com|Price to Earnings Ratio BNTX (BioNTech)|ABVX (ABIVAX) - Company Value to Net Income|P/E Multiple ADMA (ADMA Bio)|Business Payback Period Protagonist Corp (PTGX)|IMVT - Price to Earnings Ratio|kiniksa.com (KNSA) - Price to Earnings Ratio|Grifols (GRFS) - Price to Earnings Ratio|Price to Earnings Ratio Adaptive Biotech|Price to Earnings Ratio CLDX|P/E Multiple Aurinia Corp|Price to Earnings Ratio BioCryst (BCRX)|veratx.com - Price to Earnings Multiple|P/E Multiple DNTH (Dianthus Therapeutics, Inc.)|Pharvaris NV (PHVS) - Market Cap to Earnings|Tourmaline Corp - P/E Multiple|PGEN - P/E Multiple|PHAR: P/E Multiple|NKTR (nektar.com) - Price to Earnings Ratio|UPB (Upstream Bio) - P/E Multiple|Price to Earnings Ratio Zenas Bio (ZBIO)|P/E Multiple IMNM|GOSS - Market Cap to Earnings|Price to Earnings Ratio KalVista Pharmaceuticals KALV|septerna.com - Price to Earnings Ratio|PVLA - Price to Earnings Ratio|SVRA: Price to Earnings Ratio|RIGL: P/E Multiple|Market Cap to Earnings AnaptysBio Inc. (ANAB)|Price to Earnings Ratio Astria Therapeutics|ENGN: Company Value to Net Income|P/E Multiple RAPT|P/E Multiple aerovatetx.com (JBIO)|Aclaris - Price to Earnings Ratio|Company Value to Net Income KYTX|Tiziana Life Sciences - P/E Multiple|CABA: Price to Earnings Ratio|VTYX: P/E Multiple|THTX - Business Payback Period|Price to Earnings Ratio Avalo Therapeutics Inc.|Market Cap to Earnings Eledon Pharmaceuticals, Inc ELDN|Price to Earnings Ratio Agenus (AGEN)|Price to Earnings Ratio CLYM (climbbio.com)|Price to Earnings Ratio Zura Bio ZURA|aTyr Pharma Inc (ATYR) - Market Cap to Earnings|Adagene Corp - P/E Multiple|Market Cap to Net Income Ratio ImageneBio Inc (IMA)|STTK: P/E Multiple|EQ - Business Payback Period|CNTB (Connect Biopharma Holdings) - P/E Multiple|Price to Earnings Ratio Immunic Inc (IMUX)|Price to Earnings Ratio Atara Biotherapeutics (ATRA)|Business Payback Period inflarx.de|P/E Multiple XFOR (X4 Pharmaceuticals)|P/E Multiple Adicet Bio Inc. ACET|Celularity Corp - P/E Multiple|INMB: Price to Earnings Ratio|BRNS: P/E Multiple|Price to Earnings Ratio Kezar Life Sciences Inc|Price to Earnings Ratio SAB Biotherapeutics|Price to Earnings Ratio AKTX|Price to Earnings Ratio Enlivex Therapeutics (ENLV)|QTTB: Market Cap to Net Income|P/E Multiple GOVX (GeoVax Labs Inc)|Company Value to Net Income EDSA|iBio, Inc. - P/E Multiple|CARM - P/E Multiple|XTL Biopharmaceuticals Ltd. (XTLB) - Price to Earnings Ratio|Bolt Biotherapeutics, Inc. - Company Value to Net Income|Price to Earnings Ratio HCW Biologics, Inc.|Price to Earnings Ratio Aptevo (APVO)|P/E Multiple AIM|P/E Multiple aditxt.com (ADTX)|GRI Bio - Price to Earnings Ratio|Company Value to Net Income XRTX|ReShape Lifesciences - P/E Multiple|Business Payback Period Revelation Biosciences Corp REVB|Indaptus Therapeutics (INDP) - Price to Earnings Ratio|Price to Earnings Ratio scinai.com|Price to Earnings Ratio CalciMedica Inc|Price to Earnings Ratio Affimed Therapeutics (AFMD)|Price to Earnings Ratio ALLK (Allakos Inc.)|P/E Multiple hookipapharma.com (HOOK)|Price to Earnings Ratio IGM Biosciences IGMS|ITOS: Price to Earnings Multiple|Ocean Biomedical - P/E Multiple|Market Cap to Earnings TC BioPharm (Holdings) Plc|THRD: P/E Multiple